We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Auris Medical Holding AG | NASDAQ:EARS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.045 | 3.02 | 3.10 | 0 | 01:00:00 |
Zug, Switzerland, May 11, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today provided a business update and announced financial results for the first quarter ended March 31, 2017.
"The first quarter was one of continued progress for all programs and recognition of the significant unmet medical need of acute inner ear hearing loss with receipt of fast track designation for AM-111. In addition, we recently announced results from the AMPACT studies that confirm the long-term safety of Keyzilen®," commented Thomas Meyer, Auris Medical's founder, Chairman and Chief Executive Officer. "We are now moving toward key development milestones that reflect our work to address what are known as the big three otology disorders: hearing loss, tinnitus and vertigo. For AM-111 in hearing loss, we expect to complete enrollment of the Phase 3 HEALOS trial in the upcoming weeks. Furthermore, we continue to progress with the Phase 3 Keyzilen® TACTT3 trial for tinnitus and are preparing to initiate a second Phase 1 trial for AM-125 in vertigo. We look forward to reviewing these development programs at our Key Opinion Leader event on June 16 in New York City."
Development Program Updates
AM-111 for Acute Inner Ear Hearing Loss
Keyzilen® (AM-101) for Acute Inner Ear Tinnitus
AM-125 for Vertigo
Other Developments
First Quarter 2017 Financial Results
The Company continues to expect that its operating expenses in 2017 will be in the range of CHF 28 to 32 million and that existing cash and cash equivalents will enable the funding of operations into the first quarter of 2018.
Upcoming Events
Key Opinion Leader Meeting & Webcast Scheduled for June 16, 2017
Auris Medical will host a Key Opinion Leader breakfast at 8 am ET on Friday, June 16, 2017, in New York City. The meeting will focus on Auris Medical's development-stage pipeline and feature a keynote presentation by Elias Michaelides, MD, who serves as Associate Professor of Surgery, Otolaryngology and Director of the Hearing and Balance Program at Yale School of Medicine.
To reserve a seat, please contact Cindy McGee via e-mail at investors@aurismedical.com. A live webcast of the event will be available in the Investor Relations section of the Auris Medical website at www.aurismedical.com and a replay of the presentation will be available following the event.
Today's Conference Call & Webcast Information
Auris Medical will host a conference call and webcast to discuss the first quarter 2017 financial results and to provide a general business update today, May 11, 2017, at 8 am ET (2 pm CET). To participate in this conference call, dial 1-877-280-3459 (USA) or +1-646-254-3374 (International), and enter passcode 5733572. A live webcast of the conference call will be available in the Investors section of the Auris Medical website at www.aurismedical.com and a replay of the conference call will be available following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing intranasal betahistine for Meniere's disease and vestibular vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."
Forward-looking Statements
This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, prevailing market conditions, whether the Company will consummate the offering of shares and warrants on the expected terms, or at all, the satisfaction of closing conditions related to the offering and risks related to the application of the net proceeds, if any, from the offering. There can be no assurance that the Company will be able to complete the offering at the anticipated size or on the anticipated terms, or at all. In any event, the Company may continue to need additional funding and may be unable to raise capital when needed, which could force the Company to delay, reduce or eliminate its product development programs or commercialization efforts. Other risks and uncertainties relating to the Company's business include the timing and conduct of clinical trials of Auris Medical's product candidates, including the likelihood that the TACTT3 clinical trial with Keyzilen® will not meet its endpoints, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual Report on Form 20-F and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, investors@aurismedical.com
Media contact: David Schull, Russo Partners, 1-858-717-2310,david.schull@russopartnersllc.com
AURIS MEDICAL HOLDING AGCondensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Loss (unaudited) For the Three Months Ended March 31, 2017 and 2016 (in CHF)
THREE MONTHSENDED MARCH 31 | ||||
2017 | 2016 | |||
Research and development | (5,981,419) | (6,140,175) | ||
General and administrative | (1,425,491) | (1,222,032) | ||
Operating loss | (7,406,910) | (7,362,207) | ||
Interest income | 31,297 | 10,885 | ||
Interest expense | (421,435) | (2,745) | ||
Foreign currency exchange loss, net | (338,160) | (1,544,845) | ||
Revaluation gain from derivative financial instruments | 233,123 | - | ||
Transaction costs | (506,234) | - | ||
Loss before tax | (8,408,319) | (8,898,912) | ||
Income tax gain | 8,191 | - | ||
Net loss attributable to owners of the Company | (8,400,128) | (8,898,912) | ||
Other comprehensive loss: | ||||
Items that will never be reclassified to profit or loss | ||||
Remeasurements of defined benefit liability | 227,827 | (260,469) | ||
Items that are or may be reclassified to profit or loss | ||||
Foreign currency translation differences | 19,925 | 41,820 | ||
Other comprehensive income/(loss) | 247,752 | (218,649) | ||
Total comprehensive loss attributable to owners of the Company | (8,152,376) | (9,117,561) | ||
Basic and diluted loss per share | (0.22) | (0.26) |
AURIS MEDICAL HOLDING AG Condensed Consolidated Interim Statement of Financial Position (unaudited) (in CHF)
MARCH 31, 2017 | DECEMBER 31,2016 | |||
ASSETS | ||||
Non-current assets | ||||
Property and equipment | 336,350 | 369,294 | ||
Intangible assets | 1,556,823 | 1,482,520 | ||
Other non-current financial assets | 76,702 | 114,778 | ||
Total non-current assets | 1,969,875 | 1,966,592 | ||
Current assets | ||||
Other receivables | 371,451 | 296,531 | ||
Prepayments | 877,280 | 952,595 | ||
Cash and cash equivalents | 33,846,525 | 32,442,222 | ||
Total current assets | 35,095,256 | 33,691,348 | ||
Total assets | 37,065,131 | 35,657,940 | ||
EQUITY AND LIABILITIES | ||||
Equity | ||||
Share capital | 17,731,881 | 13,731,881 | ||
Share premium | 113,348,971 | 112,838,815 | ||
Foreign currency translation reserve | (63,619) | (83,544) | ||
Accumulated deficit | (120,462,704) | (112,344,303) | ||
Total shareholders' equity attributable to owners of the Company | 10,554,529 | 14,142,849 | ||
Non-current liabilities | ||||
Loan | 8,954,361 | 10,151,498 | ||
Derivative financial instruments | 4,974,474 | 117,132 | ||
Employee benefits | 1,895,110 | 2,092,434 | ||
Deferred tax liabilities | 188,391 | 196,582 | ||
Total non-current liabilities | 16,012,336 | 12,557,646 | ||
Current liabilities | ||||
Loan | 3,295,145 | 2,212,706 | ||
Trade and other payables | 2,094,386 | 1,837,997 | ||
Accrued expenses | 5,108,735 | 4,906,742 | ||
Total current liabilites | 10,498,266 | 8,957,445 | ||
Total liabilities | 26,510,602 | 21,515,091 | ||
Total equity and liabilities | 37,065,131 | 35,657,940 |
1 Year Auris Medical Chart |
1 Month Auris Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions